Bridgeway Capital Management’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

Bridgeway Capital Management’s Portfolio NVIV Stock Details NVIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-33	Closed	-$13K	–	1449
2019 Q3	$13K	Hold	33	–	–	﹤0.01%	1303
2019 Q2	$19K	Hold	33	–	–	﹤0.01%	1299
2019 Q1	$39K	Sell	33 -2	-6%	-$2.32K	﹤0.01%	1321
2018 Q4	$39K	Buy	+35	New	+$50.8K	﹤0.01%	1344
2018 Q2	–	Sell	-1	Closed	-$13K	–	1493
2018 Q1	$13K	Sell	1 -7	-88%	-$78.4K	﹤0.01%	1375
2017 Q4	$112K	Hold	8	–	–	﹤0.01%	1325
2017 Q3	$215K	Hold	8	–	–	﹤0.01%	1269
2017 Q2	$393K	Buy	8 +3	+60%	+$164K	﹤0.01%	1152
2017 Q1	$367K	Hold	5	–	–	﹤0.01%	1153
2016 Q4	$381K	Hold	5	–	–	0.01%	1171
2016 Q3	$616K	Hold	5	–	–	0.01%	992
2016 Q2	$524K	Hold	5	–	–	0.01%	1032
2016 Q1	$633K	Buy	+5	New	+$536K	0.01%	950

Other funds holding NVIV

PCM

Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

ICM

IMS Capital Management Portland, Oregon $217M AUM 18.69% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bridgeway Capital Management's NVIV Position: Q4 2019 in Review

Bridgeway Capital Management sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q4 2019, closing a stake of 33 shares — an estimated $13K sold.

Bridgeway Capital Management first reported a position in NVIV in Q1 2016 and held it in 13 quarters. The position peaked at $633K in Q1 2016. 12 funds tracked by Wall St. Rank hold NVIV as of Q4 2019.

Bridgeway Capital Management reported no remaining InVivo Therapeutics Holdings Corp position as of Q4 2019 after selling out during the quarter.
Bridgeway Capital Management sold 33 InVivo Therapeutics Holdings Corp shares in Q4 2019, an estimated $13K.
Bridgeway Capital Management first reported a position in InVivo Therapeutics Holdings Corp in Q1 2016 and held it in 13 quarters.
Bridgeway Capital Management's InVivo Therapeutics Holdings Corp position peaked at $633K in Q1 2016.
12 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q4 2019.

Based on Bridgeway Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.